[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367275-105":59,"doc-detail-367275-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dibenzo-a-c-phenazin-11-ylphenyl-methanone-sblj23-a-novel-selective-inhibitor-targeting-jak2v617f-mutation-in-myeloproliferative-neoplasms","Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23) - a novel selective inhibitor targeting JAK2V617F mutation in myeloproliferative neoplasms","","The JAK2V617F mutation drives the pathogenesis of myeloproliferative neoplasms (MPN) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, creating an urgent need for inhibitors that are both selective and safer. High-throughput virtual screening, molecular dynamics simulations, and binding free energy calculations were used to identify candidates against wild and mutant JAK2. SBLJ23 preferentially targeted JAK2V617F, showing stable protein-ligand interactions, an IC50 of 522.4 nM, reduced phospho-JAK2/phospho-STAT3 signaling, and induced G2/M arrest, supporting further optimization for clinical development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dibenzo-a-c-phenazin-11-ylphenyl-methanone-sblj23-a-novel-selective-inhibitor-targeting-jak2v617f-mutation-in-myeloproliferative-neoplasms/367275/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dibenzo-a-c-phenazin-11-ylphenyl-methanone-sblj23-a-novel-selective-inhibitor-targeting-jak2v617f-mutation-in-myeloproliferative-neoplasms/367275.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does the JAK2V617F mutation play in myeloproliferative neoplasms?","Question",{"text":112,"@type":113},"JAK2V617F is central to the pathogenesis of MPN by driving aberrant proliferation and survival of hematopoietic cells through constitutive JAK-STAT signaling.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SBLJ23 identified as a JAK2V617F inhibitor?",{"text":117,"@type":113},"SBLJ23 was selected using computational high-throughput virtual screening, molecular dynamics simulations, and binding free energy calculations, followed by in vitro validation in cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What key experimental effects did SBLJ23 produce in JAK2V617F-positive cells?",{"text":121,"@type":113},"SBLJ23 showed specificity for JAK2V617F, inhibited cell proliferation, induced G2/M cell cycle arrest, and significantly reduced phospho-JAK2 and phospho-STAT3 levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367275,1790610083,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","ONCOLOGY RESEARCH 2025 33(3): 675-685 ARTICLE  \nDibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2V617F mutation in myeloproliferative neoplasms  \nMOHAMMAD ABOHASSAN; MESFER MOHAMMAD AL SHAHRANI; SARAH KHALED ALOUDA; PRASANNA RAJAGOPALAN* Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 61413, Saudi Arabia  \nKey words: JAK2V617F mutation, Myeloproliferative neoplasms, Kinase inhibitors, High-throughput virtual screening, Molecular dynamics simulation  \nAbstract: Background: The JAK2V617F mutation plays a crucial part in the pathogenesis of myeloproliferative neoplasms (MPN), which includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myeloﬁbrosis (PMF) leading to aberrant proliferation and survival of hematopoietic cells. Alongside the challenges of drug resistance and side effects, identifying novel compounds that selectively target JAK2V617F could provide more effective and safer therapeutic options for patients with MPNs. Materials and Methods: We employed computational approaches like high-throughput virtual screening, molecular dynamics simulations (MDS), and binding free energy calculations to identify inhibitors targeting wild and mutant JAK2 kinases. JAK2V617F positive HEL, wild type JAK2 positive TF-1, and non-cancerous Vero cells were used for in vitro validations. Results: SBLJ23 emerged as a top candidate inhibitor with speciﬁcity for JAK2V617F. Protein-ligand interaction studies and MDS revealed stable interactions and binding of SBLJ23 over the simulation period, with Root Mean Square Deviation (RMSD) indicating consistent binding after 1t15ns. SBLJ23 displayed a half maximal inhibitory concentration (IC50) value of 522.4 nM against the JAK2 enzyme.  \nThe compound exhibited inhibition of cell proliferation in HEL and TF-1 cells, with half maximal cell growth inhibitory concentration (GI50) values of 2.51 and 15.87 µM, respectively. Moreover, SBLJ23 induced G2/M cell cycle arrest in HEL cells to facilitate apoptosis in these cell lines. The compound signiﬁcantly reduced the percentage of phospho JAK2 and phospho STAT3 in HEL cells. Conclusion: High binding afﬁnity, stable interaction proﬁle, favorable binding free energy, and in vitro validations claim SBLJ23 as a potential lead compound against JAK2V617Fand suggest further development and optimization towards clinical application in managing myeloproliferative  \nneoplasms.  \nIntroduction  \nThe conditions collectively referred to as myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), primary myeloﬁbrosis (PMF), and polycythemia vera (PV) . The overproduction of platelet-forming cells and red blood cells in the bone marrow is a characteristic of these disorders [1] . These disorders are marked by a clonal expansion of hematopoietic cells and carry a heightened propensity for progressing to acute myeloid leukemia (AML) . The pathogenesis of myeloproliferative neoplasms (MPN) involves several key-signaling pathways that drive  \n*Address correspondence to: Prasanna Rajagopalan, [prachu.rg@gmail.com](prachu.rg@gmail.com)  \nReceived: 18 July 2024; Accepted: 27 September 2024;  \nPublished: 28 February 2025  \nDoi: 10.32604/or.2024.056256  \nthe abnormal proliferation and survival of hematopoietic cells [2] . Central to these pathways is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which is often dysregulated due to mutations in genes such as JAK2, MPL, and CALR [3,4] . The JAK2, in particular, is prevalent across PV, ET, and PMF, leading to constitutive activation of the JAK-STAT signaling cascade. This activation promotes unchecked cell division and resistance to apoptosis [5] . Additionally, the mitogenactivated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways contribute to the malignant phenotype by enhancing cell proliferation, survival, and differentiati","cbCaiayRrYVN1MFG","https://ap.wps.com/l/cbCaiayRrYVN1MFG","pdf",22106624,11,"English","# Introduction\n## Background on MPN and JAK-STAT signaling\n## Role of JAK2V617F mutation in MPN","[{\"question\":\"What role does the JAK2V617F mutation play in myeloproliferative neoplasms?\",\"answer\":\"JAK2V617F is central to the pathogenesis of MPN by driving aberrant proliferation and survival of hematopoietic cells through constitutive JAK-STAT signaling.\"},{\"question\":\"How was SBLJ23 identified as a JAK2V617F inhibitor?\",\"answer\":\"SBLJ23 was selected using computational high-throughput virtual screening, molecular dynamics simulations, and binding free energy calculations, followed by in vitro validation in cell lines.\"},{\"question\":\"What key experimental effects did SBLJ23 produce in JAK2V617F-positive cells?\",\"answer\":\"SBLJ23 showed specificity for JAK2V617F, inhibited cell proliferation, induced G2/M cell cycle arrest, and significantly reduced phospho-JAK2 and phospho-STAT3 levels.\"}]","Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23) - a novel selective inhibitor targeting JAK2V617F mutation in myeloproliferative neoplasms | PDF",1790170040,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12e48d4d5b895e31c5df9d02fe7c6c44.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/235dbdd5547125092baee94fdd48fe45.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ed5c6e90cb76875ab77dfb1050d054e.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cce6b4d4619c3ad8baec1ff3e393583.webp",980,1385]